Clare M. Wieland

Ms. Clare M. Wieland

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CWClare M. Wieland
Clare M. Wieland
ATAshley M. Tuin
Ashley M. Tuin
EDElizabeth Julia Dort
Elizabeth Julia Dort
AHAlexander G. Hall
Alexander G. Hall
MKMridula Krishnan
Mridula Krishnan
MVManasa Velagapudi
Manasa Velagapudi
Background: Burkitt lymphoma (BL) accounts for 10–35% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while investigating impact of treatment modalities in HIV-associated BL. Methods: Using the 2004–2019 NCDB, we identified 4312 patients with stage 3 or 4 BL who had a known HIV status and received either chemotherapy alone or chemotherapy and immunotherapy. Time to death was evaluated using Kaplan–Meier survival estimates. Risk of death was evaluated using an extended multivariable Cox model adjusted for multiple factors and with a Heaviside function for HIV status by time period (0–3 month vs. 3–60 month). Results: Of the 4312 patients included, 1514 (35%) had HIV. For months 0–3 from time of diagnosis, HIV status was not associated with a statistically significant increase in risk of death (HR = 1.04, 95% CI: 0.86, 1.26, p = 0.6648). From month 3to 60, positive HIV status was associated with a 55% increase in risk of death compared to those without HIV (95% CI: 1.38, 1.75, p < 0.0001). Further, this difference in hazard rates (0–3 vs. 3–60) was statistically significant (HR = 1.49, 95% CI: 1.22–1.82, p < 0.001). Conclusions: There is an increased mortality rate from months 3 to 60 in BL patients with HIV compared to patients without HIV. Additionally, risk of death in the first 3 months is significantly decreased by 45% in patients with HIV treated with combination chemotherapy and immunotherapy compared to patients without HIV receiving combination chemotherapy and immunotherapy, providing valuable clinical insight into treatment decision making in the care of HIV-associated BL.

1 June 2025 in JU Open Plus
Verified
Journal Article
Open access
CMClaire S. Malhotra
Claire S. Malhotra
SVSankalp Vinayak
Sankalp Vinayak
CWClare M. Wieland
Clare M. Wieland
ETEmma A. Thomsen
Emma A. Thomsen
PPPeter S. Palencia
Peter S. Palencia
MFMichael P. Feloney
Michael P. Feloney
Purpose: To determine the glycerin concentration that best maintains the volume of the 5-cc and 10-cc balloons of the Duette double-balloon chronic indwelling catheter (DBCIC). Materials and Methods: Over the course of 2 experimental trials, 16 Fr double-balloon catheters were filled with glycerin solutions of various concentrations (0%-40% v/v in sterile water) and normal saline and placed in synthetic urine. Balloon diameters were recorded over time, and final balloon volumes were measured on day 28. Results: The 30% and 20% glycerin solutions were most effective at minimizing volume change of the 5-cc and 10-cc balloons, respectively, in both trials. Furthermore, linear regression analysis of volume change (ΔV) vs glycerin concentration revealed minimization (ΔV = 0) for the 5-cc balloon occurred at 27% glycerin in the first trial and 30% glycerin in the second trial. Minimization for the 10-cc balloon occurred at 16% glycerin in both the first and second trials. Conclusions: For the sake of simplicity and ease of performing calculations and dilutions in a busy clinical environment, we recommend that 30% glycerin be used as a filling solution for the 5-cc balloon and 15% glycerin be used as a filling solution for the 10-cc balloon of the DBCIC in vivo. Further studies conducted in vivo are needed to investigate the effectiveness of these filling solutions in clinical practice.

12 May 2025 in Urology
Verified
Journal Article
Closed access
PPPeter S. Palencia
Peter S. Palencia
DDDanielle B. Dilsaver
Danielle B. Dilsaver
CWClare M. Wieland
Clare M. Wieland
RCRichard A. Cheung
Richard A. Cheung
RHRobert W. Hu
Robert W. Hu
JDJoan C. Delto
Joan C. Delto